The US Food and Drug Administration (FDA) has granted fast track designation to Nanjing Leads Biolabs core product opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, for the first-line treatment of advanced or metastatic biliary tract cancer (BTC).
This is the second FDA Fast Track Designation for opamtistomig, following its previous designation in extrapulmonary neuroendocrine carcinoma (EP-NEC).
The BTC designation was granted just nine days after submission, reflecting the urgency of addressing unmet medical needs in this patient population and the potential clinical value of the programme.
The FDA has also recommended that the Company promptly initiate discussions regarding the US registration plans for opamtistomig in combination with chemotherapy for BTC. These developments provide important regulatory momentum for the programme and may help streamline its development and registration pathway in the United States.
Fast Track Designation is an FDA programme designed to facilitate the development and expedite the review of drugs and biologics intended to treat serious or life-threatening conditions and to address unmet medical needs.
The designation provides opportunities for more frequent communication with the FDA and guidance on key development considerations, including clinical trial design and data requirements.
If applicable regulatory criteria are met, fast track-designated products may also qualify for rolling review of their marketing applications, allowing completed sections to be submitted for review before the entire application is finalised. These mechanisms can facilitate development planning and potentially expedite the regulatory review process.
For opamtistomig, the designation represents an important step in advancing a differentiated immunotherapy approach for first-line advanced BTC, a disease characterised by poor prognosis and limited effective treatment options.
